Comparative Pharmacology
Head-to-head clinical analysis: NINTEDANIB ESYLATE versus SPRYCEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NINTEDANIB ESYLATE versus SPRYCEL.
NINTEDANIB ESYLATE vs SPRYCEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
Dasatinib is a dual tyrosine kinase inhibitor targeting BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds to the ATP-binding site of BCR-ABL and inhibits proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
150 mg orally twice daily, 12 hours apart, taken with food.
100 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Terminal elimination half-life is approximately 3–4 hours for dasatinib, with a longer half-life of 8–10 hours for its active metabolite; clinical context: supports twice-daily dosing.
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor